- Home
- GKOS vs ASLE Comparison
GKOS vs ASLE Comparison
Compare GKOS & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- ASLE
- Stock Information
- Founded
- GKOS 1998
- ASLE 2008
- Country
- GKOS United States
- ASLE United States
- Employees
- GKOS N/A
- ASLE N/A
- Industry
- GKOS Medical/Dental Instruments
- ASLE Industrial Specialties
- Sector
- GKOS Health Care
- ASLE Consumer Discretionary
- Exchange
- GKOS Nasdaq
- ASLE Nasdaq
- Market Cap
- GKOS 5.1B
- ASLE N/A
- IPO Year
- GKOS 2015
- ASLE N/A
- Fundamental
- Price
- GKOS $93.70
- ASLE $6.88
- Analyst Decision
- GKOS Strong Buy
- ASLE Strong Buy
- Analyst Count
- GKOS 13
- ASLE 3
- Target Price
- GKOS $155.00
- ASLE $9.00
- AVG Volume (30 Days)
- GKOS 1.0M
- ASLE 550.1K
- Earning Date
- GKOS 04-30-2025
- ASLE 05-07-2025
- Dividend Yield
- GKOS N/A
- ASLE N/A
- EPS Growth
- GKOS N/A
- ASLE N/A
- EPS
- GKOS N/A
- ASLE 0.11
- Revenue
- GKOS $383,481,000.00
- ASLE $345,066,000.00
- Revenue This Year
- GKOS $27.84
- ASLE $14.51
- Revenue Next Year
- GKOS $27.99
- ASLE $18.41
- P/E Ratio
- GKOS N/A
- ASLE $61.36
- Revenue Growth
- GKOS 21.85
- ASLE 3.16
- 52 Week Low
- GKOS $77.91
- ASLE $4.53
- 52 Week High
- GKOS $163.71
- ASLE $9.40
- Technical
- Relative Strength Index (RSI)
- GKOS 46.72
- ASLE 45.72
- Support Level
- GKOS $87.17
- ASLE $6.38
- Resistance Level
- GKOS $98.86
- ASLE $6.62
- Average True Range (ATR)
- GKOS 5.12
- ASLE 0.34
- MACD
- GKOS 1.70
- ASLE -0.02
- Stochastic Oscillator
- GKOS 71.96
- ASLE 49.29
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.